As­traZeneca, Am­gen tout Phase 2a Tezspire da­ta in COPD ahead of Dupix­ent de­ci­sion

As­traZeneca and Am­gen laid out the full Phase 2a dataset for Tezspire in COPD at the Amer­i­can Tho­racic So­ci­ety’s In­ter­na­tion­al Con­fer­ence on Sun­day, pro­vid­ing a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER